Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y 12 Antagonist | Zendy

David Iyú | Zendy; Jackie R. Glenn | Zendy; Ann E. White | Zendy; Sue Fox | Zendy; Stan Heptinstall | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y ₁₂ Antagonist

Author(s) -

David Iyú,

Jackie R. Glenn,

Ann E. White,

Sue Fox,

Stan Heptinstall

Publication year - 2010

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.110.219501

Subject(s) - adenosine , adenosine diphosphate , ticagrelor , chemistry , prasugrel , pharmacology , antagonist , platelet , platelet aggregation inhibitor , adenosine a1 receptor , p2y receptor , adenosine deaminase , medicine , biochemistry , endocrinology , receptor , adenosine receptor , biology , purinergic receptor , agonist , platelet aggregation , clopidogrel , aspirin

To investigate whether adenosine diphosphate (ADP)-derived adenosine might inhibit platelet aggregation, especially in the presence of a P2Y₁₂ antagonist, where the effects of ADP at the P2Y₁₂ receptor would be prevented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research